B2M and head and neck squamous cell carcinoma: B2M expression was not associated with OS in the non–immunotherapy-treated TCGA HNSCC cohort [HR, 1.071; 95% CI, 0.924–1.242; P = 0.363] (Supplementary Fig. S5).